A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Trial Details

NCT ID
NCT07218146
Phase
PHASE3
Sponsor
Zai Lab (Shanghai) Co., Ltd.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • ZL-1310
  • Investigator's Choice of Therapy
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Sacramento, California, United States|38.58157,-121.4944
  • Aurora, Colorado, United States|39.72943,-104.83192
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Clermont, Florida, United States|28.54944,-81.77285

Key Eligibility Criteria

  • Age \>/= 18 years, or considered an adult by local regulations, at the time of consent
  • Signed informed consent
  • Histologically or cytologically confirmed SCLC. Received 1L platinum-based systemic therapy and had documented disease progression during or after …
  • Measurable disease according to RECIST v1.1 as assessed by the investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →